Last viewed:
AGNPF
Prices are updated after-hours
AGNPF
|
$0.089
75K
|
Health Technology
(0.0% 1d)
(34.3% 1m)
(-59.9% 1y)
(0.0% 2d)
(28.6% 3d)
(28.6% 7d)
(515.07%
volume)
Earnings Calendar:
Market Cap: $ 1,926,028
http://www.algernonpharmaceuticals.com
Sec
Filling
|
Patents
| n/a employees
(CA) Algernon Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the development of repurposed therapeutic drugs. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, and idiopathic pulmonary fibrosis. The company was founded on January 22, 2015 and is headquartered in Vancouver, Canada.
urea
kidney diseases
kidney
add to watch list
Paper trade
email alert is off
Press-releases
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
Published: 2024-04-24
(Crawled : 12:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| Email alert
Add to watchlist
drug
conference
stroke
research
for
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
Published: 2024-04-11
(Crawled : 11:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| 25.87%
| O: -100.0%
H: NaN%
C: Infinity%
ceo
pharmaceuticals
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
Published: 2024-04-01
(Crawled : 11:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| 9.76%
| O: 0.37%
H: 4.5%
C: -11.69%
drug
stroke
pharmaceuticals
research
program
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2024-03-27
(Crawled : 16:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| 45.16%
| O: 25.81%
H: 0.0%
C: 0.0%
acquisition
pharmaceuticals
research
program
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Published: 2024-01-31
(Crawled : 12:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| 50.5%
| O: 5.02%
H: 13.06%
C: 11.46%
patent
treat
pharmaceuticals
grant
chinese
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
Published: 2024-01-11
(Crawled : 12:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| Email alert
Add to watchlist
patent
japan
fibrosis
pharmaceuticals
Algernon Pharmaceuticals Announces Closing of Private Placement
Published: 2023-12-27
(Crawled : 21:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| 80.0%
| O: 9.2%
H: 20.51%
C: 15.38%
pharmaceuticals
Algernon Pharmaceuticals Announces Increase to Private Placement
Published: 2023-12-27
(Crawled : 12:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| 80.0%
| O: 0.0%
H: 0.0%
C: 0.0%
pharmaceuticals
Algernon Pharmaceuticals Announces Private Placement
Published: 2023-12-13
(Crawled : 01:00)
- globenewswire.com
AGNPF
|
$0.089
75K
|
Health Technology
| 57.89%
| O: 3.68%
H: 0.0%
C: -5.92%
pharmaceuticals
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
Published: 2023-11-30
(Crawled : 17:00)
- biospace.com/
AGNPF
|
$0.089
75K
|
Health Technology
| 58.45%
| O: 12.32%
H: 0.0%
C: 0.0%
patent
treat
pharmaceuticals
grant
chinese
nash
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount